Syndax Pharmaceuticals Fell While Sales Rose

Strong trial results, rising sales of Revuforj and Niktimvo, and bullish analyst reports have kept Syndax Pharmaceuticals in the headlines this year. Holding Syndax Pharmaceuticals from the start of the year would have meant a 20.2% loss, including dividends. If you had made that call on 1 January, the gap between upbeat news and a negative outcome raises a simple question: Which expectations about Syndax now matter most to reassess?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

The move put Syndax Pharmaceuticals in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.

The Two Syndax Pharmaceuticals Stories Investors Were Weighing

The shares cost US$21.01 at the start of the period, and Syndax Pharmaceuticals came with two very different stories attached to that quote.

The bullish narrative set fair value at US$36.55, built on an assumption that revenue could grow 97.8% a year while profit margins moved from deep losses to 7.2%, which in turn was used to justify a future P/E of 90.6x.

The bearish view pointed to fair value of US$19. It argued that heavy dependence on Revuforj and Niktimvo, together with regulatory and pricing pressure, could restrain a 79.7% revenue growth assumption and leave the stock on a 27.9x future P/E.

What The Evidence Did To The Syndax Pharmaceuticals Argument

The biggest update for Syndax Pharmaceuticals was Q2 2026 revenue of US$72.79 million and a loss of US$49.36 million. Both revenue and profit moved in a positive direction, and net margin improved to a loss of 67.8%. That shift supported the optimistic growth story, yet the business still did not reach profitability, so the strongest bull case on margins remained unproven.

The practical takeaway is clear. When a narrative leans on fast operating leverage, track the gap between rising sales and the remaining loss, not just the growth rate. For any other biotech, compare the trend in net margin and absolute profit against the original P/E and margin assumptions investors were asked to believe.

What You Are Really Paying For In Syndax Pharmaceuticals Today

Syndax Pharmaceuticals now trades at US$16.99, with this Narrative’s Fair Value sitting above the current price based on its own assumptions rather than settled fact. The argument leans on label expansion for Revuforj and Niktimvo alongside a broader pipeline to support future revenue and margin improvement.

To treat the share price fall as a potential opening rather than a warning, you would need to believe Syndax can overcome concentrated product risk, regulatory scrutiny, and high R&D spending well enough to convert its lead assets and pipeline into durable profitability.

"While current strong cash reserves and initial profitability on relapsed/refractory indications give Syndax operational flexibility, future growth will demand sustained clinical success and rapid penetration into new indications; any slowdown in patient identification, increased payer hurdles, or stagnation in expansion trials could quickly reverse momentum in revenue and return the company to operating losses."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Where Could You Get There Earlier?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 46% below our estimate - uses a culture-focused banking model while integrating a merger and scaling specialty platforms.
• Company 2 - 41% below our estimate - shifts toward broader commercial lending as low cost deposits reshape its margin profile.
• Company 3 - 22% below our estimate - expands beyond trackers into storage and inverter offerings to deepen project revenue per site.

That is three of the list. See every one of the 28 undervalued companies on it →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com